,
Siyab Aamir,
Nida Hassan,
Karrar Shaaban Imran,
Gulnaz Bahtiyarova,
Younes Nabgouri,
Nnamdi Cletus Opara,
Zhang Ming*
End-stage liver disease (ESLD) represents the terminal phase of chronic liver injury, characterized by overt clinical manifestations and severe complications that significantly impair the quality of life. The condition often culminates in a variety of symptoms, including jaundice, ascites, and hepatic encephalopathy, which reflect the liver's inability to perform its essential functions. Liver transplantation remains the definitive treatment for ESLD; however, limitations in donor organ availability necessitate exploration of alternative therapeutic strategies. we present a case of a 71-year-old Asian male with decompensated post-hepatitis B cirrhosis, who had a one-year history of hematemesis and melena. Endoscopic evaluation confirmed the presence of esophageal-gastric varices, further corroborating portal hypertension and hypersplenism. This patient underwent treatment with autologous bone marrow-derived mesenchymal stem cell (BM-MSC) transplantation. Following the procedure, the patient demonstrated significant clinical improvement, suggesting the safety and potential feasibility of BM-MSC transplantation for patients with ESLD. The field of BM-MSC transplantation has witnessed significant progress in recent years, emerging as a promising therapeutic approach for ESLD. This innovative treatment modality harnesses the regenerative capabilities of stem cells to promote liver repair and function. Notably, BM-MSCs possess immunomodulatory properties that may mitigate inflammation and fibrosis in the liver, thereby addressing some of the underlying pathophysiology associated with ESLD. This case presentation highlights the potential application of BM-MSC therapy in patients with decompensated cirrhosis. The findings underscore the need for further research and refinement of clinical application techniques to fully realize the broad therapeutic possibilities of BM-MSC transplantation for ESLD. As we advance our understanding of stem cell therapies, it is crucial to conduct larger studies to evaluate long-term outcomes and establish standardized protocols for treatment.
| Published in | American Journal of Internal Medicine (Volume 12, Issue 6) |
| DOI | 10.11648/j.ajim.20241206.13 |
| Page(s) | 120-124 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Stem Cells, End-Stage Liver Disease (ESLD), Hepatitis B
| [1] | Aydin, S., Sağraç, D., & Şahin, F. Differentiation Potential of Mesenchymal Stem Cells into Pancreatic β-Cells. (0065-2598 (Print)). |
| [2] | Fox, R. K. When to consider liver transplant during the management of chronic liver disease. (1557-9859 (Electronic)). |
| [3] | Hernández, R., Jiménez-Luna, C., Perales-Adán, J., Perazzoli, G., Melguizo, C., & Prados, J. Differentiation of Human Mesenchymal Stem Cells towards Neuronal Lineage: Clinical Trials in Nervous System Disorders. (1976-9148 (Print)). |
| [4] | Jopling, C., Boue S Fau - Izpisua Belmonte, J. C., & Izpisua Belmonte, J. C. Dedifferentiation, transdifferentiation and reprogramming: three routes to regeneration. (1471-0080 (Electronic)). |
| [5] | Karagiannakis, D. A.-O. X., & Stefanaki, K. Spleen stiffness: a predictive factor of dismal prognosis in liver cirrhosis. (1865-7265 (Electronic)). |
| [6] | Kim, T. S., & Choi, D. A.-O. Liver Dysfunction in Sepsis. (2233-6869 (Electronic)). |
| [7] | Liu, J. A.-O., Yuan, Z., & Wang, Q. Pluripotent Stem Cell-derived Strategies to Treat Acute Liver Failure: Current Status and Future Directions. (2225-0719 (Print)). |
| [8] | Miró, J. M., Laguno M Fau - Moreno, A., Moreno A Fau - Rimola, A., & Rimola, A. Management of end stage liver disease (ESLD): what is the current role of orthotopic liver transplantation (OLT)? (0168-8278 (Print)). |
| [9] | Park, C. W., Kim, K. S., Bae, S., Son, H. K., Myung, P. K., Hong, H. J., & Kim, H. Cytokine secretion profiling of human mesenchymal stem cells by antibody array. (2005-3606 (Print)). |
| [10] | Philips, C. A., & Kedarisetty, C. K. Palliative Care for Patients with End-Stage Liver Disease. (0973-6883 (Print)). |
| [11] | Tekin, A., Beduschi, T., Vianna, R., & Mangus, R. S. Multivisceral transplant as an option to transplant cirrhotic patients with severe portal vein thrombosis. (1743-9159 (Electronic)). |
| [12] | Uccelli, A., Moretta, L., & Pistoia, V. (2008). Mesenchymal stem cells in health and disease. Nature Reviews Immunology, 8(9), 726-736. |
| [13] | Xu, M., Chen, Y., & Artru, F. A.-O. Acute decompensation of cirrhosis versus acute-on-chronic liver failure: What are the clinical implications? (2050-6414 (Electronic)). |
| [14] | Yu, S., Yu, S., Liu, H., Liao, N., & Liu, X. (2023). Enhancing mesenchymal stem cell survival and homing capability to improve cell engraftment efficacy for liver diseases. Stem Cell Research & Therapy, 14(1), 235. |
APA Style
Saeed, M., Aamir, S., Hassan, N., Imran, K. S., Bahtiyarova, G., et al. (2024). Autologous Bone Marrow-Derived Mesenchymal Stem Cell Transplantation for Decompensated Post-Hepatitis B Cirrhosis: A Case Report. American Journal of Internal Medicine, 12(6), 120-124. https://doi.org/10.11648/j.ajim.20241206.13
ACS Style
Saeed, M.; Aamir, S.; Hassan, N.; Imran, K. S.; Bahtiyarova, G., et al. Autologous Bone Marrow-Derived Mesenchymal Stem Cell Transplantation for Decompensated Post-Hepatitis B Cirrhosis: A Case Report. Am. J. Intern. Med. 2024, 12(6), 120-124. doi: 10.11648/j.ajim.20241206.13
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ajim.20241206.13,
author = {Muhammad Saeed and Siyab Aamir and Nida Hassan and Karrar Shaaban Imran and Gulnaz Bahtiyarova and Younes Nabgouri and Nnamdi Cletus Opara and Zhang Ming},
title = {Autologous Bone Marrow-Derived Mesenchymal Stem Cell Transplantation for Decompensated Post-Hepatitis B Cirrhosis: A Case Report
},
journal = {American Journal of Internal Medicine},
volume = {12},
number = {6},
pages = {120-124},
doi = {10.11648/j.ajim.20241206.13},
url = {https://doi.org/10.11648/j.ajim.20241206.13},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajim.20241206.13},
abstract = {End-stage liver disease (ESLD) represents the terminal phase of chronic liver injury, characterized by overt clinical manifestations and severe complications that significantly impair the quality of life. The condition often culminates in a variety of symptoms, including jaundice, ascites, and hepatic encephalopathy, which reflect the liver's inability to perform its essential functions. Liver transplantation remains the definitive treatment for ESLD; however, limitations in donor organ availability necessitate exploration of alternative therapeutic strategies. we present a case of a 71-year-old Asian male with decompensated post-hepatitis B cirrhosis, who had a one-year history of hematemesis and melena. Endoscopic evaluation confirmed the presence of esophageal-gastric varices, further corroborating portal hypertension and hypersplenism. This patient underwent treatment with autologous bone marrow-derived mesenchymal stem cell (BM-MSC) transplantation. Following the procedure, the patient demonstrated significant clinical improvement, suggesting the safety and potential feasibility of BM-MSC transplantation for patients with ESLD. The field of BM-MSC transplantation has witnessed significant progress in recent years, emerging as a promising therapeutic approach for ESLD. This innovative treatment modality harnesses the regenerative capabilities of stem cells to promote liver repair and function. Notably, BM-MSCs possess immunomodulatory properties that may mitigate inflammation and fibrosis in the liver, thereby addressing some of the underlying pathophysiology associated with ESLD. This case presentation highlights the potential application of BM-MSC therapy in patients with decompensated cirrhosis. The findings underscore the need for further research and refinement of clinical application techniques to fully realize the broad therapeutic possibilities of BM-MSC transplantation for ESLD. As we advance our understanding of stem cell therapies, it is crucial to conduct larger studies to evaluate long-term outcomes and establish standardized protocols for treatment.
},
year = {2024}
}
TY - JOUR T1 - Autologous Bone Marrow-Derived Mesenchymal Stem Cell Transplantation for Decompensated Post-Hepatitis B Cirrhosis: A Case Report AU - Muhammad Saeed AU - Siyab Aamir AU - Nida Hassan AU - Karrar Shaaban Imran AU - Gulnaz Bahtiyarova AU - Younes Nabgouri AU - Nnamdi Cletus Opara AU - Zhang Ming Y1 - 2024/11/28 PY - 2024 N1 - https://doi.org/10.11648/j.ajim.20241206.13 DO - 10.11648/j.ajim.20241206.13 T2 - American Journal of Internal Medicine JF - American Journal of Internal Medicine JO - American Journal of Internal Medicine SP - 120 EP - 124 PB - Science Publishing Group SN - 2330-4324 UR - https://doi.org/10.11648/j.ajim.20241206.13 AB - End-stage liver disease (ESLD) represents the terminal phase of chronic liver injury, characterized by overt clinical manifestations and severe complications that significantly impair the quality of life. The condition often culminates in a variety of symptoms, including jaundice, ascites, and hepatic encephalopathy, which reflect the liver's inability to perform its essential functions. Liver transplantation remains the definitive treatment for ESLD; however, limitations in donor organ availability necessitate exploration of alternative therapeutic strategies. we present a case of a 71-year-old Asian male with decompensated post-hepatitis B cirrhosis, who had a one-year history of hematemesis and melena. Endoscopic evaluation confirmed the presence of esophageal-gastric varices, further corroborating portal hypertension and hypersplenism. This patient underwent treatment with autologous bone marrow-derived mesenchymal stem cell (BM-MSC) transplantation. Following the procedure, the patient demonstrated significant clinical improvement, suggesting the safety and potential feasibility of BM-MSC transplantation for patients with ESLD. The field of BM-MSC transplantation has witnessed significant progress in recent years, emerging as a promising therapeutic approach for ESLD. This innovative treatment modality harnesses the regenerative capabilities of stem cells to promote liver repair and function. Notably, BM-MSCs possess immunomodulatory properties that may mitigate inflammation and fibrosis in the liver, thereby addressing some of the underlying pathophysiology associated with ESLD. This case presentation highlights the potential application of BM-MSC therapy in patients with decompensated cirrhosis. The findings underscore the need for further research and refinement of clinical application techniques to fully realize the broad therapeutic possibilities of BM-MSC transplantation for ESLD. As we advance our understanding of stem cell therapies, it is crucial to conduct larger studies to evaluate long-term outcomes and establish standardized protocols for treatment. VL - 12 IS - 6 ER -
Department of Internal Medicine, Polyclinic Hospital, Islamabad, Pakistan
Department of Surgery, Zhejiang Chinese Medical University, Hangzhou, China
Department of Medicine, Holy Family Hospital, Rawalpindi, Pakistan
Faculty of Medicine, University of Warith Al-Anbiya, Karbala, Iraq
Department of Internal Medicine, Formerly: First Pavlov State Medical University, Saint Petersburg, Russia
Department of Internal Medicine, Formerly: First Pavlov State Medical University, Saint Petersburg, Russia
College of Medicine, Imo State University, Orlu, Nigeria
Department of Internal Medicine, First Affiliated Hospital of Zhejiang University, Hangzhou, China
Information